FDA Update: FDA Delays Baricitinib Review & Removes Bupropion & Varenicline Warnings

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Eli Lilly and Co. News release: U.S. FDA extends review period for baricitinib, an investigational rheumatoid arthritis treatment. 2017 Jan 13.
2. U.S. Food and Drug Administration. FDA drug safety communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings. 2017 Jan 16.